Difference between revisions of "Rosai-Dorfman-Destombes disease"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "][" to "] [")
Line 15: Line 15:
 
==Consensus guidelines==
 
==Consensus guidelines==
 
*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://www.ncbi.nlm.nih.gov/pubmed/29720485 PubMed]
 
*'''2018:''' Abla et al. [http://www.bloodjournal.org/content/131/26/2877.long Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease] [https://www.ncbi.nlm.nih.gov/pubmed/29720485 PubMed]
 +
 +
==[https://www.nccn.org NCCN]==
 +
*[https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdf NCCN Guideliines - Histiocytic Neoplasms]
  
 
=All lines of therapy=
 
=All lines of therapy=

Revision as of 13:22, 9 March 2021

Section editor
GauravGoyal.jpg
Gaurav Goyal, MD
UAB
Birmingham, AL

Social-twitter-icon.png GauravGoyalMD
1 regimens on this page
1 variants on this page


Guidelines

Consensus guidelines

NCCN

All lines of therapy

Cobimetinib monotherapy

back to top

Regimen

Study Evidence
Diamond et al. 2019 (MSK 15-216) Pilot, <20 pts in this arm

Note: there were N=2 patients with this type of histiocytosis.

Targeted therapy

28-day cycles

References

  1. MSK 15-216: Diamond EL, Durham BH, Ulaner GA, Drill E, Buthorn J, Ki M, Bitner L, Cho H, Young RJ, Francis JH, Rampal R, Lacouture M, Brody LA, Ozkaya N, Dogan A, Rosen N, Iasonos A, Abdel-Wahab O, Hyman DM. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar;567(7749):521-524. Epub 2019 Mar 13. link to original article contains verified protocol link to PMC article PubMed